Overview

The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes

Status:
Completed

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

It is well-known that women with previous gestational diabetes mellitus are in risk of developing type 2 diabetes later in life; approximately half of the women develop overt type 2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous gestational diabetes with the aim of reducing the risk of developing type 2 diabetes.

Phase:

Phase 4

Details

Lead Sponsor:

Tina Vilsboll

Collaborators:

Aarhus University Hospital
Herlev Hospital
Hillerod Hospital, Denmark
Hvidovre University Hospital
Novo Nordisk A/S
Rigshospitalet, Denmark
The Novo Nordisk Foundation Center for Basic Metabolic Research
University of Copenhagen

Treatments:

Liraglutide